GlobalData: Upcoming Novartis chronic heart failure drug expected to dominate ... PharmaLive (press release) (subscription) Research and consulting firm GlobalData has released a new report, PharmaPoint: Chronic Heart Failure - Global Drug Forecast and Market Analysis to 2022 and forecasts global sales of Novartis' combination drug LCZ-696 to reach a massive $1.86 billion ... |
